Charles Schwab Investment Management Inc. Lowers Stake in Sangamo Therapeutics, Inc. $SGMO

Charles Schwab Investment Management Inc. reduced its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 3.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,097,834 shares of the biopharmaceutical company’s stock after selling 41,418 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.48% of Sangamo Therapeutics worth $720,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. GSA Capital Partners LLP boosted its stake in shares of Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after acquiring an additional 934,649 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Sangamo Therapeutics during the 1st quarter worth about $47,000. Cerity Partners LLC boosted its stake in shares of Sangamo Therapeutics by 439.2% during the 1st quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 44,800 shares in the last quarter. Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics by 14.2% during the 1st quarter. Golden State Equity Partners now owns 371,943 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 46,259 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Sangamo Therapeutics during the 1st quarter worth about $193,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on SGMO shares. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. Barclays cut their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.54 on Wednesday. The stock has a market cap of $162.74 million, a PE ratio of -1.86 and a beta of 1.20. The firm has a fifty day moving average price of $0.53 and a 200 day moving average price of $0.65. Sangamo Therapeutics, Inc. has a 1-year low of $0.41 and a 1-year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. As a group, equities analysts expect that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.